AI-Generated Filing Summaries

Cardinal Health announced Gregory B. Kenny's retirement from the Board of Directors and as Board Chair effective March 20, 2026, with no disagreements on company matters, and appointed Patricia A. Hemingway Hall as the new Board Chair effective immediately. The company will release third quarter fiscal 2026 earnings on April 30, 2026, and remains confident in its fiscal 2026 outlook.

Woori Financial Group Inc. held its annual general meeting of shareholders on March 23, 2026, approving FY2025 separate and consolidated financial statements, amendments to the Articles of Incorporation, election of one standing director and three independent directors, and maximum limit on directors’ compensation, all with over 93% votes in favor. Consolidated FY2025 net income was 3,227,508 million KRW with total dividends of 1,360 KRW per common share.

Sealed Air Corporation announced on March 23, 2026, that it has received all regulatory approvals required to complete its pending acquisition pursuant to the November 16, 2025 merger agreement with Sword Purchaser, LLC (affiliated with Clayton, Dubilier & Rice, LLC) and Sword Merger Sub, Inc. The transaction is expected to close in April 2026, subject to remaining customary closing conditions, after which Sealed Air will become privately held and its common stock will no longer trade on the NYSE.

Gamehaus Holdings Inc. announced unaudited financial results for the second quarter of fiscal 2026 ended December 31, 2025, reporting total revenue of US$26.3 million, operating income of US$0.9 million, and net income of US$0.9 million. The Company provided third quarter revenue guidance of US$24 million to US$26 million and updated its share repurchase plan, with US$459,000 in Class A ordinary shares repurchased as of December 31, 2025.

Woori Financial Group Inc. disclosed on March 23, 2026, that it determined eligibility as a 'high dividend company' under Article 104-27 of the Act on Restriction on Special Cases Concerning Taxation, supporting its 2026 Corporate Value Enhancement Plan. It reported a 32.0% dividend payout ratio for 2025, with KRW 998,467,866,200 in dividends, up 12.1% from KRW 891,045,067,200 in 2024.

Tower Semiconductor and Coherent demonstrated 400Gbps/lane data transmission using a silicon modulator in Tower's production-ready SiPho process, achieving a clear open eye at 420 Gb/s PAM4 with Coherent’s InP CW high power laser. This breakthrough targets next-generation 3.2T optical transceivers for pluggable and Co-Packaged Optics in AI datacenter connections.

On March 19, 2026, YHN Acquisition I Limited deposited $150,000 into the trust account established in connection with its initial public offering to extend the time available to complete a business combination from March 19, 2026, to June 19, 2026.

On March 19, 2026, YHN Acquisition I Limited deposited $150,000 into the trust account established in connection with its initial public offering to extend the time available to complete a business combination from March 19, 2026, to June 19, 2026.

A Paradise Acquisition Corp. made available to holders of its Class A ordinary shares its PFIC Annual Statement for the taxable year beginning January 1, 2025 and ending December 31, 2025, attached as Exhibit 99.1. The statement discloses per-share ordinary earnings of 0.0006050296 USD, no net capital gains, and no distributions, to assist U.S. shareholders with QEF elections under Section 1295.

Coeur Mining completed its acquisition of New Gold via a stock-for-stock arrangement, issuing approximately 393 million shares of common stock at a 0.4959 exchange ratio and entered a new $1.0 billion senior secured revolving credit facility. The company also amended its certificate of incorporation to increase authorized common shares to 1.3 billion, appointed two new directors, issued updated reserves/resources for New Afton and Rainy River, and authorized a $750 million share repurchase program plus a $0.02 semi-annual dividend.

Avalo Therapeutics, Inc. (AVTX) reported a net loss of $78.3 million for FY 2025, a $43.1 million increase from $35.1 million in FY 2024, driven by heightened research and development (R&D) expenses of $50.1 million (up $25.6 million YoY) tied to the Phase 2 LOTUS trial for lead candidate abdakibart (AVTX-009) in hidradenitis suppurativa (HS). Total revenues were minimal at $59K, reflecting legacy product wind-down, compared to $0.4 million in 2024. General and administrative expenses rose to $22.9 million (up $5.7 million YoY), primarily from stock-based compensation. Operating expenses totaled $73.0 million, yielding a $72.9 million operating loss. Other net expense of $5.2 million included a $9.5 million change in derivative liability fair value. Cash used in operations was $51.5 million, with $98.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025, sufficient to fund operations into 2028. Balance sheet showed $116.5 million total assets and $83.0 million stockholders' equity. Forward-looking, focus remains on LOTUS topline data in Q2 2026 and Phase 3 planning, with no near-term revenue expected as a clinical-stage biotech.

Insmed Incorporated announced positive topline results from the Phase 3b ENCORE study evaluating ARIKAYCE plus azithromycin and ethambutol versus placebo plus the same multidrug therapy in 425 patients with newly diagnosed Mycobacterium avium complex lung infection, meeting the primary endpoint of change from baseline in Respiratory Symptom Score at Month 13 (17.77 vs 14.66 points, p=0.0299) and all multiplicity-controlled secondary culture conversion endpoints. The company plans supplemental NDA filing with FDA and data submission to PMDA in second half of 2026 for potential label expansion.

Avalo Therapeutics, Inc. announced its financial results for the year ended December 31, 2025, reporting a net loss of $78.3 million, research and development expenses of $50.1 million, and cash, cash equivalents, and short-term investments of $98.3 million expected to fund operations into 2028. Topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) for hidradenitis suppurativa is expected in the second quarter of 2026.

RenovoRx, Inc. entered into a Securities Purchase Agreement on March 17, 2026, for a private placement offering to 15 investors, closing on March 20, 2026, issuing 8,438,790 shares of common stock, pre-funded warrants for 2,200,000 shares, and milestone warrants for 5,319,392 shares for gross proceeds of approximately $10 million before fees. The offering relies on Section 4(a)(2) and Rule 506 of Regulation D exemptions from registration.

BioLineRx Ltd., a clinical-stage biopharma company focused on oncology and rare diseases, reported FY 2025 revenues of $1.2 million, a 96% decline from $28.9 million in FY 2024, primarily due to the November 2024 out-licensing of motixafortide rights to Ayrmid (excluding Asia and solid tumors) and shutdown of U.S. commercialization. Revenues in 2025 consisted solely of $1.2 million in royalties from Ayrmid on APHEXDA (motixafortide) sales for stem cell mobilization. Net loss narrowed to $2.0 million from $9.2 million YoY, driven by reduced operating expenses post-commercial wind-down (R&D $8.1M vs $9.2M; no sales/marketing vs $23.6M) and $8.1M non-operating income from warrant fair value changes. Total assets stood at $40.9M, with cash/cash equivalents/short-term deposits at $20.9M ($3.2M cash + $17.6M deposits), supporting operations into H1 2027. Cash burn eased: operating -$8.1M (vs -$43.9M), investing -$8.5M, financing +$8.9M. Equity rose to $23.3M, liabilities fell to $17.6M. Forward-looking, focus shifts to GLIX1 development via Tetragon (40% owned) and motixafortide solid tumors (PDAC Phase 2b ongoing). Management highlights reduced burn rate and potential milestones/royalties from partnerships.

Prudential plc purchased 369,491 ordinary shares of 5 pence each from JP Morgan Securities plc on 20 March 2026 at prices ranging from £10.5250 to £10.9400 per share, with an average price of £10.7274. The company intends to cancel these shares, resulting in 2,529,583,440 shares in issue and total voting rights.

Prudential plc purchased 369,491 ordinary shares of 5 pence each from JP Morgan Securities plc on 20 March 2026 at prices ranging from £10.5250 to £10.9400 per share, with an average price of £10.7274. The company intends to cancel these shares, resulting in 2,529,583,440 shares in issue and total voting rights.

Pyxis Oncology reported full year 2025 financial results with total revenues of $13.9 million, net loss of $79.6 million or ($1.28) per share, and cash position of $68.3 million sufficient to fund operations into Q4 2026. The company completed target enrollment in the Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC and announced leadership appointments.

Dr. Reddy’s Laboratories Ltd. announced the launch of Obeda®, India’s first DCGI-approved generic semaglutide injection for type 2 diabetes, available in 2 mg and 4 mg pre-filled pens at INR 4,200 per month per patient. A Phase III study with 312 participants confirmed non-inferior efficacy and comparable safety to the innovator drug.

Prudential Public Limited Company disclosed a Form 6-K with a TR-1 notification from Norges Bank reporting its total voting rights in the issuer at 4.039570% (102,214,467 voting rights) as of March 19, 2026, following an acquisition or disposal of voting rights that crossed a threshold, up from a prior total of 4.020780%.

Prudential Public Limited Company disclosed a Form 6-K with a TR-1 notification from Norges Bank reporting its total voting rights in the issuer at 4.039570% (102,214,467 voting rights) as of March 19, 2026, following an acquisition or disposal of voting rights that crossed a threshold, up from a prior total of 4.020780%.

ECARX Holdings, Inc. (Nasdaq: ECX) appointed Dylan D. Jeng as Chief Financial Officer, effective immediately on March 23, 2026. Mr. Jeng, based in Singapore, will oversee global financial strategy, planning, treasury, investor relations, and financial operations to support accelerated global expansion.

ECARX Holdings, Inc. (Nasdaq: ECX) appointed Dylan D. Jeng as Chief Financial Officer, effective immediately on March 23, 2026. Mr. Jeng, based in Singapore, will oversee global financial strategy, planning, treasury, investor relations, and financial operations to support accelerated global expansion.

BioLineRx Ltd. reported audited 2025 financial results with $1.2 million revenues, $2.0 million net loss, and $20.9 million cash balance providing runway into first half of 2027. The company is on track to initiate Phase 1/2a GLIX1 trial in glioblastoma by end of March 2026, received USPTO Notice of Allowance for key GLIX1 patent to 2040, and accelerated enrollment in motixafortide pancreatic cancer trial with interim readout in 2026.

Victory Capital Holdings, Inc. issued a press release on March 23, 2026, defending its proposal to acquire Janus Henderson Group plc at $40.00 cash plus 0.250 shares of VCTR per JHG share (total $57.05 per share), countering Trian's $49.00 per share offer and misinformation while highlighting its strong financial track record.

Pyxis Oncology, Inc. (PYXS) reported FY 2025 revenues of $13.9 million, down 14% YoY from $16.1 million in FY 2024, primarily due to $11.0 million from sale of royalty rights under Simcere Agreement and $2.8 million milestone, offset by no royalty revenues versus $8.1 million prior year. Total costs and operating expenses fell 7% to $98.3 million, driven by no $21.0 million IPR&D impairment (versus 2024) but higher R&D at $73.7 million (up 26% YoY from $58.7 million, led by $14.1 million MICVO increase). Loss from operations improved to -$84.4 million from -$89.5 million; net loss widened slightly to -$79.6 million from -$77.3 million due to $1.4 million tax expense. Balance sheet shows $91.5 million total assets, with $66.8 million in cash equivalents and marketable securities (down from prior implied higher). Operating cash use was $63.5 million, partially offset by $58.9 million investing inflows from securities redemptions. Management notes cash runway into Q4 2026 but substantial doubt on going concern, emphasizing need for funding amid MICVO trials. Forward-looking, focus on mid-2026 data readouts for MICVO monotherapy/combo in R/M HNSCC; partnerships eyed for pipeline.

TransAlta Corporation hosted its 2026 Investor Day on March 23, 2026, discussing Alberta power market outlook, strategic priorities, financial position, and growth path to 2029 and beyond. President and CEO John Kousinioris announced his transition to retirement, with Executive Vice President Finance and CFO Joel Hunter as incoming President and CEO.

TransAlta Corporation hosted its 2026 Investor Day on March 23, 2026, discussing Alberta power market outlook, strategic priorities, financial position, and growth path to 2029 and beyond. President and CEO John Kousinioris announced his transition to retirement, with Executive Vice President Finance and CFO Joel Hunter as incoming President and CEO.

Suzano S.A. disclosed FY2025 audited financials with net profit of BRL 13.4 billion, proposed minimum dividends of BRL 1.39 billion (mostly paid as interim), board of 9 directors for election, management compensation cap of BRL 136 million for 2026, and bylaw amendments for corporate purpose expansion into minerals and capital increase to BRL 24.3 billion ahead of AEGM on April 23, 2026.

Haleon plc purchased 7,833,121 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026, with transactions on 16-20 March 2026 across London Stock Exchange, CBOE (UK)/BXE, and CBOE (UK)/CXE. Following settlement, registered share capital is 8,941,771,041 ordinary shares, with 12,591,821 treasury shares and 8,929,179,220 voting ordinary shares.